Hepatitis delta coinfection in persons with HIV: misdiagnosis and disease burden in Italy

References

• Sureau C, Negro F. The hepatitis delta virus: replication and pathogenesis. J Hepatol. 2016;64(Suppl1):S102–S116.
   PubMedGoogle Scholar
• Gaeta GB, Precone DF, Cozzi-Lepri A, et al. Multiple viral infections. J Hepatol. 2006;44:S108–13.
   PubMed Web of Science ®Google Scholar
• Wranke A, Pinheiro Borzacov LM, Parana R, et al. Clinical and virological heterogeneity of hepatitis delta in different regions world-wide: the Hepatitis Delta International Network (HDIN). Liver Int. 2018;38:842–850.
   PubMed Web of Science ®Google Scholar
• Rizzetto M, Hamid S, Negro F. The changing scenario of hepatitis D. J Hepatol. 2021;75:1200–1211.
   Google Scholar
• Miao Z, Zhang S, Ou X, et al. Estimating the global prevalence, disease progression and clinical outcome of hepatitis delta virus infection. J Infect Dis. 2020;221:177–1687.
   Web of Science ®Google Scholar
• Chen HY, Shen DT, Ji DZ, et al. Prevalence and burden of hepatitis D virus infection in the global population: a systematic review and meta-analysis. Gut. 2019;68:512–521.
   PubMed Web of Science ®Google Scholar
• Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020;73:523–532.
   PubMed Web of Science ®Google Scholar
• Gaeta GB, Stroffolini T, Smedile A, et al. Hepatitis delta in Europe: vanishing or refreshing? Hepatology. 2007;46:1312–1313.
   PubMed Web of Science ®Google Scholar
• Cross TJS, Rizzi P, Horner M, et al. The increasing prevalence of hepatitis delta virus (HDV) Infection in South London. J Med Virol. 2008;80:277–282.
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Heidrich B, Mann MP. Hepatitis D virus infection – not a vanishing disease in Europe! Hepatology. 2007;45:1331–1332.
   PubMed Web of Science ®Google Scholar
• Manesis EK, Vourli G, Dalekos G, et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. J Hepatol. 2013;59:949–956.
   PubMed Web of Science ®Google Scholar
• Rizzetto M. Hepatitis delta: thirty years after. J Hepatol. 2009;50:1043–1050.
   PubMed Web of Science ®Google Scholar
• Romeo R, Del Ninno E, Rumi M, et al. A 28-year study of the course of hepatitis Delta: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009;136:1629–1638.
   PubMed Web of Science ®Google Scholar
• Niro GA, Smedile A, Ippolito AM, et al. Outcome of chronic delta hepatitis in Italy: a long-term cohort study. J Hepatol. 2010;53:834–840.
   PubMed Web of Science ®Google Scholar
• Béguelin C, Moradpour D, Sahli R, et al. Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. J Hepatol. 2017;66:297–303.
   PubMed Web of Science ®Google Scholar
• Fernández-Montero JV, Vispo E, Barreiro P, et al. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. Clin Infect Dis. 2014;58:1549–1553.
   PubMed Web of Science ®Google Scholar
• Alfaiate D, Clément S, Gomes D, et al. Chronic hepatitis D and hepatocellular carcinoma: a systematic review and meta-analysis of observational studies. J Hepatol. 2020;73:533–539.
   PubMed Web of Science ®Google Scholar
• Brancaccio G, Gaeta GB. Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection. Int J Antimicrob Agents. 2019;54:697–701.
   PubMed Web of Science ®Google Scholar
• Niro GA, Ciancio A, Gaeta GB, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis Delta. Hepatology. 2006;44:713–720.
   PubMed Web of Science ®Google Scholar
• Castelnau C, Le Gal F, Ripault MP, et al. Efficacy of peginterferon alpha-2b in chronic hepatitis delta: relevance of quantitative RT-PCR for follow-up. Hepatology. 2006;44:728–735.
   PubMed Web of Science ®Google Scholar
• Yurdaydin C, Keskin O, Kalkan C, et al. Interferon treatment duration in patients with chronic delta hepatitis and its effect on the natural course of the disease. J Infect Dis. 2018;217:1184–1192.
   PubMed Web of Science ®Google Scholar
• Heidrich B, Yurdaydın C, Kabacam G, et al. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. 2014;60:87–97.
   PubMed Web of Science ®Google Scholar
• Kabaçam G, Onder FO, Yakut M, et al. Entecavir treatment of chronic hepatitis D. Clin Infect Dis. 2012;55:645–650.
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Yurdaydin C, Hardtke S, et al. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomized placebo controlled, phase 2 trial. Lancet Infect Dis. 2019;19:275–286.
   PubMed Web of Science ®Google Scholar
• Brancaccio G, Fasano M, Grossi A, et al. Clinical outcomes in patients with hepatitis Delta, cirrhosis and persistent hepatitis B virus replication and receiving long-term entecavir or tenofovir. Aliment Pharmacol Ther. 2019;49:1071–1076.
   PubMed Web of Science ®Google Scholar
• Soriano V, Vispo E, Sierra-Enguita R, et al. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. AIDS. 2014;28:2389–2394.
   PubMed Web of Science ®Google Scholar
• Olivero A, Smedile A. Hepatitis Delta virus diagnosis. Semin Liver Dis. 2012;32:220–227.
   PubMed Web of Science ®Google Scholar
• Wranke A, Heidrich B, Ernst S, et al. Anti-HDV IgM as a marker of disease activity in hepatitis Delta. Plos One. 2014;9:e101002.
   PubMed Web of Science ®Google Scholar
• Spaan M, Carey I, Bruce M, et al. Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1. J Hepatol. 2020;72:1097–1104.
   PubMed Web of Science ®Google Scholar
• Monforte AD, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naive patients. I.CO.N.A. study group; Italian Cohort Antiretroviral-Naive Patients. AIDS. 2000;14:499–507.
   PubMed Web of Science ®Google Scholar
• Shanyinde M, Girardi E, Puoti M, et al. Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection? BMC Infect Dis. 2019;19:1291.
   Google Scholar
• Soriano V, Grint D, d’Arminio Monforte A, et al. Hepatitis delta in HIV-infected individuals in Europe. AIDS. 2011;25:1987–1992.
   PubMed Web of Science ®Google Scholar
• Beguelin C, Atkinson A, and Boyd A, et al. Hepatitis delta infection among persons with HIV in Europe. CROI, Virtual Meeting; 2021. Abs 452.
   Google Scholar
• Ramos-Rincon JM, Pinargote H, Ramos-Belinchón C, et al. Hepatitis delta in patients hospitalized in Spain (1997–2018). AIDS. 2021;35:2311–2318.
   PubMed Web of Science ®Google Scholar
• Dong M, Wu J, Yu X, et al. Validation and comparison of seventeen noninvasive models for evaluating liver fibrosis in Chinese hepatitis B patients. Liver Int. 2018;38:1560–1562.
   Web of Science ®Google Scholar
• Sterling RK, King WC, Wahed AS, et al.; HIV-HBV Cohort Study of the Hepatitis B Research Network. Evaluating noninvasive markers to identify advanced fibrosis by liver biopsy in HBV/HIV co-infected adults. Hepatology. 2020;71:411–421.
   PubMed Web of Science ®Google Scholar
• Béguelin C, Friolet N, Moradpour D, et al. Impact of tenofovir on hepatitis delta virus replication in the Swiss human immunodeficiency Virus Cohort Study. Clin Infect Dis. 2017;64:1275–1278.
   PubMed Web of Science ®Google Scholar
• Boyd A, Miailhes P, Brichler S, et al. Effect of tenofovir with and without interferon on hepatitis D virus replication in HIV-hepatitis B virus-hepatitis D virus-infected patients. AIDS Res Hum Retroviruses. 2013;29:1535–1540.
   PubMed Web of Science ®Google Scholar
• Gaeta GB, Stornaiuolo G, Precone DF, et al. Epidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. J Hepatol. 2003;39:1036–1041.
   PubMed Web of Science ®Google Scholar
• Raimondo G, Brunetto MR, Pontisso P, et al. Longitudinal evaluation reveals a complex spectrum of virological profiles in hepatitis B virus/hepatitis C virus-coinfected patients. Hepatology. 2006;43:100–107.
   PubMed Web of Science ®Google Scholar
• Perez-Vargas J, Amirache F, Boson B, et al. Enveloped viruses distinct from HBV induce dissemination of hepatitis D virus in vivo. Nat Commun. 2019;10(1):2098.
   PubMedGoogle Scholar
• Brancaccio G, Gaeta GB. Letter: clinical outcomes of patients with D infection in liver transplant setting-authors’ reply. Aliment Pharmacol Ther. 2020;51:484.
   PubMed Web of Science ®Google Scholar
• Schaper M, Rodriguez-Frias F, Jardi R, et al. Quantitative longitudinal evaluations of hepatitis delta virus RNA and hepatitis B virus DNA shows a dynamic, complex replicative profile in chronic hepatitis B and D. J Hepatol. 2010;52:658–664.
   PubMed Web of Science ®Google Scholar
• Yurdaydin C, Abbas Z, Buti M, et al. Treating chronic hepatitis delta: the need of surrogate markers of treatment efficacy. J Hepatol. 2019;70:1008–1015.
   PubMed Web of Science ®Google Scholar
• Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut. 2021;70:1782–1794.
   PubMed Web of Science ®Google Scholar
• Soriano V, Mendoza C, Barreiro P, et al. Envisioning a hepatitis delta cure with new antivirals. Future Microbiol. 2021;16:927–930.
   PubMed Web of Science ®Google Scholar